血液系统恶性肿瘤患者中的 COVID-19：一项以色列全国性回顾性分析，特别关注治疗与结局

This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.

7%) developed severe/critical respiratory infection, 178 (61. 4%) were hospitalized, and 60 (20. 0%) died. Age > 70 years was associated with severe/critical disease ( p = 0. 036) and mortality ( p = 0. 023), hypertension with severe/critical disease ( p = 0. 046) and hospitalization ( p = 0. 001), active haemato-oncological treatment with hospitalization ( p = 0. 009), and remdesivir treatment was associated with decreased mortality ( p = 0. 021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit.

In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.